Leadership Changes and Financial Updates in Diabetes Tech Companies

Insulet Appoints New CFO, Anticipates Strong Q3 Growth

Insulet, a prominent player in diabetes technology, has announced the appointment of Flavia Pease as its new Chief Financial Officer, effective September 30, 2025. Pease, who previously served as CFO at Charles River Laboratories, brings over two decades of experience from Johnson & Johnson, where she held key roles in both medical device and pharmaceutical segments.

The appointment comes as part of a leadership transition at Insulet, with new CEO Ashley McEvoy, another J&J veteran, at the helm. McEvoy expressed confidence in Pease's ability to guide Insulet's next growth phase, citing her impressive track record and leadership experience in global companies.

Pease's appointment has been well-received by industry analysts, with J.P. Morgan's Robbie Marcus noting her extensive healthcare and device experience. The incoming CFO will step down from her current position on Insulet's board, which she has held since 2024, to take on the new role.

In a positive financial update, Insulet expects to surpass its forecasted 22% to 25% revenue growth for the third quarter of 2025. The company's next earnings call is scheduled for November 6, where more details on this performance are likely to be shared.

Dexcom Leadership Transition Faces Temporary Setback

Dexcom, a leading glucose sensor manufacturer, is navigating an unexpected leadership challenge. Outgoing CEO Kevin Sayer has taken a temporary medical leave of absence as of September 14, 2025. This development comes amidst a planned leadership transition, with Sayer originally set to step down in January 2026.

In response to Sayer's absence, the company has implemented interim measures. Jake Leach, the current Chief Operating Officer and CEO-designate, will serve as interim principal executive officer while maintaining his COO responsibilities. Additionally, Mark Foletta, lead independent director of the board, will step in as interim chairman.

Dexcom has not provided details on the expected duration of Sayer's leave or any impact on the planned leadership transition. The company stated that neither Leach nor Foletta will receive additional compensation for their interim roles, emphasizing the temporary nature of these arrangements.

These developments in both Insulet and Dexcom highlight the dynamic nature of leadership in the competitive diabetes technology sector, with both companies navigating significant transitions while maintaining their focus on innovation and growth.